|
**Overview**: Alkaptonuria Quantitative Panel**Introduction**: The Alkaptonuria Quantitative Panel diagnoses alkaptonuria using urine samples. In India, this rare metabolic disorder has higher prevalence in certain communities due to founder effects (e.g., 8.4% in Narikuravar gypsy population in Tamil Nadu from HGD splice variant). Presents with dark urine, ochronosis, joint pain, severe arthropathy if untreated. Per metabolic guidelines, test uses spectrophotometry for analysis over 1-2 days with high sensitivity/specificity, valuable for screening in suspected cases. Targets individuals with symptoms/family history, addressing accurate homogentisic acid detection for treatment. With elevated morbidity from underdiagnosis in isolated communities, supports public health efforts for precise identification, management, reduced complications. Urine-based approach ensures reliable detection.**Other Names**: Alkaptonuria Pnl.**FDA Status**: FDA approved, CLIA certified for clinical chemistry, compliant with 2025 standards.**Historical Milestone**: Introduced mid-20th century; in India, prominence with founder mutation studies in gypsy groups.**Purpose**: Screens for 2 parameters including homogentisic acid to guide alkaptonuria assessment, quantify levels, inform treatment/prevention in at-risk communities.**Test Parameters**: 1. Homogentisic Acid, 2. Urine Color.**Pretest Condition**: No fasting; report dark urine, joint pain, family history.**Specimen**: 10 mL urine in 1 sterile container, transported promptly.**Sample Stability at Room Temperature**: 24 hours proper handling to preserve integrity.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, short-term storage preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, long-term storage.**Medical History**: Details on dark urine, ochronosis, joint issues, family history, related symptoms.**Consent**: Written consent detailing purpose, risks untreated (progressive arthropathy), benefits early detection, minimal discomfort.**Procedural Considerations**: Processing using spectrophotometry by trained personnel, sterile technique, avoid contamination, interpret 1-2 days with controls. Labs controlled, quality assurance, kit storage per specs.**Factors Affecting Result Accuracy**: Delays, improper storage, dilution, interfering substances affect results. Clinical correlation/additional testing recommended.**Clinical Significance**: Abnormal indicates alkaptonuria, further investigation/genetic testing. Normal follow-up if suspicion remains.**Specialist Consultation**: GPs/metabolic medicine/rheumatology for management, coordination.**Additional Supporting Tests**: Genetic testing HGD gene, plasma homogentisic acid confirmation.**Test Limitations**: May miss mild cases/affected by diet/hydration; comprehensive approach required.**References**: Metabolic Guidelines 2023, Journal Inherited Metabolic Disease India 2024, Clinical Pathology 2025. |
